Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

Inclusion Criteria: 1. Be at least 18 years of age 2. Have a confirmed diagnosis of MM 3. Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after one prior treatment. 4. Have personally signed and dated a legally effective written informed consent form prior to admission to the study. 5. Must be willing and able to understand and comply with the study requirements. Exclusion Criteria: 1. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening. 2. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.